Richard B. Gaynor, MD, joined Eli Lilly and Company as Vice President for Cancer Research and Clinical Investigation in August 2002. Currently he is Vice President of Clinical Development and Medical Affairs in the Oncology Business Unit.
Dr. Gaynor received a Bachelor of Science degree in biology from Texas Tech University and then received a doctor of medicine degree from the University of Texas Southwestern (UTSW) Medical School. He served his internship and residency in internal medicine at Parkland Memorial Hospital in Dallas, Texas. He completed a fellowship in hematology-oncology at the University of California at Los Angeles (UCLA) School of Medicine and then served on the faculty there. He received board certification in internal medicine, hematology, and medical oncology.
Prior to joining Eli Lilly, Dr. Gaynor was a Professor of Medicine and Microbiology, and held several leadership positions at the UTSW Medical Center in Dallas. He was Chief of the Division of Hematology and Oncology at UTSW, and Director of the Harold C. Simmons Comprehensive Cancer Center there, in addition to his work as the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology. He has also served on numerous National Institutes of Health (NIH) advisory committees and was elected to both the American Society of Clinical Investigation and Association of American Physicians.
Dr. Gaynor is on the editorial board of several scientific journals and has an extensive publication record totaling more than 140 scientific articles. He serves on the board of the Damon Runyon Cancer Research Foundation and the Walther Cancer Institute, as well as on several committees for the American Association for Cancer Research and other leading cancer organizations.